Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 22.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,102 shares of the specialty pharmaceutical company’s stock after purchasing an additional 743 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Jazz Pharmaceuticals were worth $505,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. IFP Advisors Inc purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $25,000. Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares during the period. Elequin Capital LP lifted its position in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $110.29 on Friday. The company has a market capitalization of $6.80 billion, a P/E ratio of 15.53, a PEG ratio of 1.04 and a beta of 0.33. The company has a 50-day moving average of $107.72 and a 200-day moving average of $120.66. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 1-year low of $95.49 and a 1-year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts’ consensus estimates of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The firm had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. During the same quarter last year, the business posted $2.68 earnings per share. The firm’s revenue for the quarter was down .5% on a year-over-year basis. Equities analysts expect that Jazz Pharmaceuticals plc will post 16.96 EPS for the current fiscal year.

Analyst Ratings Changes

JAZZ has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th. Morgan Stanley lowered their price target on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. Truist Financial boosted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday. Finally, Barclays restated an “overweight” rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $184.00.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan purchased 100,000 shares of the firm’s stock in a transaction dated Friday, May 9th. The stock was acquired at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares of the company’s stock, valued at approximately $9,826,000. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at approximately $54,487,991.25. This represents a 0.34% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,000 shares of company stock worth $355,925. 4.20% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.